We found that VX-970 prevented the establishment of HCT116 ARID1A−/− xenografts (frequency of ARID1A−/− tumour formation=27% for VX-970-treated mice versus 73% in vehicle-treated mice, P=0.027, Fisher's exact test), but had no impact on the establishment of ARID1A+/+ xenografts (frequency of ARID1A−/− tumourformation=80% for VX-970-treated mice versus 87% in vehicle-treated mice, P=1 ns by Fisher's exact test, Fig. 3c,d). The gene discussed is ARID1A; the disease is neoplasm.